In vitro susceptibility to miltefosine of amphotericin B-resistant Leishmania (Mundinia) martiniquensis
Parasitology Research · 2023
DOI: 10.1007/s00436-023-07992-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Parasitology Research, 2023. Verfasst von Chonlada Mano und 5 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Chiang Mai University, Chiang Mai, 50200, Thailand. Hauptthemen laut MEDLINE: Leishmania, Leishmaniasis, Antiprotozoal Agents, Leishmaniasis, Visceral. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Faculty of Medicine, Chiang Mai University, Thailand Graduate Institute of Science and Technology (TGIST) and NSTDA.
Abstract (Originalsprache)
Leishmania (Mundinia) martiniquensis is a newly described species that causes human visceral, disseminated, and mucocutaneous leishmaniases. Amphotericin B deoxycholate (AmpB) is the first-line drug for the treatment of leishmaniasis in Thailand; however, several relapse cases of leishmaniasis caused by L. martiniquensis have been documented. In this study, in vitro susceptibility to AmpB and miltefosine (MIL) of wild-type (before treatment, LSCM1) and two AmpB-resistant L. martiniquensis strains (an in vitro-induced AmpB-resistant strain, AmpBRP2i, and a relapse strain, LSCM1-6) were determined. Results reveal that the IC50 value and resistance index against both drugs of promastigotes and intracellular amastigotes of the AmpBRP2i and LSCM1-6 strains were statistically significantly higher than those of the LSCM1 strain suggesting that cross-resistance with MIL occurred in both AmpB-resistant strains. The results of this study advocate further investigation into mechanisms that involve the complex nature of AmpB/MIL resistance in L. martiniquensis and development of effective methods for the identification of the AmpB-resistant parasites to help delivery of appropriate treatments for patients and for epidemiological surveys to survey the potential spread of drug-resistant strains.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, Chiang Mai University, Chiang Mai, 50200, Thailand.
- Animal House Unit, Faculty of Medicine, Chiang Mai University, Chiang Mai, 50200, Thailand.
- Center of Insect Vector Study, Department of Parasitology, Faculty of Medicine, Chiang Mai University, Chiang Mai, 50200, Thailand.
- Center of Excellence in Vector Biology and Vector-Borne Disease, Department of Parasitology, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand.
- Center of Excellence in Vector Biology and Vector-Borne Disease, Department of Parasitology, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand. narissara.j@chula.ac.th.
Förderung
- Faculty of Medicine, Chiang Mai University
- Thailand Graduate Institute of Science and Technology (TGIST) and NSTDA
Zitieren
APA
Mano, C., Kongkaew, A., Tippawangkosol, P., Junkum, A., Siriyasatien, P., & Jariyapan, N. (2023). In vitro susceptibility to miltefosine of amphotericin B-resistant Leishmania (Mundinia) martiniquensis. Parasitology Research. https://doi.org/10.1007/s00436-023-07992-3
Vancouver
Mano C, Kongkaew A, Tippawangkosol P, Junkum A, Siriyasatien P, Jariyapan N. In vitro susceptibility to miltefosine of amphotericin B-resistant Leishmania (Mundinia) martiniquensis. Parasitology Research. 2023. doi:10.1007/s00436-023-07992-3
BibTeX
@article{Mano2023,
author = {Mano, Chonlada and Kongkaew, Aphisek and Tippawangkosol, Pongsri and Junkum, Anuluck and Siriyasatien, Padet and Jariyapan, Narissara},
title = {In vitro susceptibility to miltefosine of amphotericin B-resistant Leishmania (Mundinia) martiniquensis},
journal = {Parasitology Research},
year = {2023},
doi = {10.1007/s00436-023-07992-3}
}
EUVIMED